Sign inStart free

Health Care · Pharmaceutical Preparations

MNPR Monopar Therapeutics SEC Filings & Insider Trading Activity 2026

company
CIK 164546986 filings
Russell 2000
Follow MNPR for alertsAsk AI about MNPR

MNPR at a glance

Monopar Therapeutics (MNPR, SEC CIK 1645469) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Monopar Therapeutics (MNPR) reported revenue of $0 and a net loss of $13.7 million. Diluted EPS was -$1.85.
  • As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Monopar Therapeutics (MNPR) shares worth $91.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by STARR CHRISTOPHER M on October 1, 2026 of 799 shares at $79.67 per share.
  • In the last 90 days, MNPR insiders reported 0 open-market purchases ($0) and 26 open-market sales ($4.8M) on Form 4, a net sale of $4.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 26 sells
Net −$4.8M
13F holders
22 funds
$91.4M · +3 vs prior quarter
Latest 8-K
Jul 22, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY; no approved drugs and no revenues generated
  • Cash, equivalents and investments $134.3M at June 30, 2026
  • Funds expected sufficient through December 31, 2027 for ALXN1840, MNPR-101 trials and pipeline R&D
  • ALXN1840 rolling NDA submission initiated July 22, 2026, completion anticipated within months
  • Key headwind: FDA acceptance or approval of ALXN1840 NDA not assured

Risk Factors

  • No Risk Factors section provided; excerpt contains only Item 5 insider trading-plan disclosures
  • Executive and director plans authorize sales of up to 91,289 shares collectively
  • CEO plan covers up to 47,309 shares and terminates May 31, 2027
  • CFO plan covers up to 615 shares and terminates May 31, 2027

AI summary of the MNPR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Jul 22, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Rolling FDA NDA submission initiated for ALXN1840 (tiomolibdate choline) in Wilson disease
  • Regulatory milestone potentially accelerates FDA review of Monopar’s lead therapeutic candidate

Item EX-99.1: Item EX-99.1

  • Rolling NDA submission initiated for ALXN1840, advancing Monopar’s lead program toward potential U.S. approval in Wilson disease
  • FDA filing authorization enables completed sections to undergo review before the application is complete
Filed Jun 30, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • FDA granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline)
  • Designation may support regulatory incentives, including potential priority review voucher eligibility

AI summaries of MNPR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MNPR

Don't miss the next MNPR filing

  • Alerts as it files. A push when MNPR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MNPR, by share count.
  • Ask anything. An AI agent that reads every MNPR filing and answers with sources.
Follow MNPR for alertsAsk AI about MNPR
Compare plans →

MNPR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
STARR CHRISTOPHER MSellOct 1, 2026$79.67
STARR CHRISTOPHER MMOct 1, 2026$0.01
STARR CHRISTOPHER MSellOct 1, 2026$78.82
STARR CHRISTOPHER MMOct 1, 2026-
STARR CHRISTOPHER MSellOct 1, 2026$78.09
Cittadine AndrewMSep 30, 2026-
Robinson ChandlerMSep 30, 2026-
Robinson ChandlerMSep 30, 2026-
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$0$0$0
Operating Income-$8.8M-$16.2M-$16.7M
Net Income--$15.6M-$13.7M
Balance Sheet
Total Assets$7.3M$60.3M$140.7M
Equity$5.6M$55.0M$137.8M
ROE--28.3%-10.0%
Per Share
EPS$-0.61$-4.11$-1.85
Cash Flow
Operating CF-$7.9M-$6.4M-$12.2M

Source: XBRL data in Monopar Therapeutics (MNPR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate MNPR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MNPR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202622$91.4M
Q1 202619$59.0M
Q4 202518$59.9M
Q3 202513$46.2M
Q2 202514$14.7M
Q1 20259$5.9M
Q4 20242$1.2M
Q3 20241$3,000
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
Closed Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 98 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MNPR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Oct 5, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 27, 2026--
4Aug 27, 2026--
4Aug 27, 2026--
8-KAug 12, 2026--
10-QAug 12, 2026Analysis
8-KJul 22, 2026Analysis-
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jun 30, 2026--
8-KJun 30, 2026Analysis-
8-KJun 26, 2026Analysis-
8-KJun 23, 2026Analysis-
8-KMay 29, 2026Analysis
8-KMay 19, 2026Analysis
SC 13GMay 15, 2026-
8-KMay 14, 2026-
10-QMay 14, 2026Analysis

Related Health Care companies

All Health Care →

MNPR SEC filings: frequently asked questions

Are MNPR insiders buying or selling?

In the last 90 days, Monopar Therapeutics (MNPR) officers, directors and 10% owners reported no open-market purchases and 26 open-market sales worth $4.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MNPR stock?

As of June 30, 2026, the largest Monopar Therapeutics (MNPR) holders among the 13F filers tracked by SignalX were BlackRock ($32.3 million), Vanguard Capital Management LLC ($19.4 million), State Street Corp ($8.6 million), BNY Mellon ($7.1 million), Millennium Management ($4.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MNPR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Monopar Therapeutics (MNPR) reported revenue of $0 and a net loss of $13.7 million. Diluted EPS was -$1.85. The figures come from the XBRL data in the 10-K.

What did MNPR report in its latest 8-K?

Monopar Therapeutics (MNPR) filed an 8-K on July 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). Rolling FDA NDA submission initiated for ALXN1840 (tiomolibdate choline) in Wilson disease.

What are the latest MNPR SEC filings?

Monopar Therapeutics (MNPR) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on October 5, 2026.

What is MNPR's SEC CIK number?

Monopar Therapeutics (MNPR)'s SEC Central Index Key (CIK) is 1645469. EDGAR lists every MNPR filing under that number.

Ask anything about MNPR

The research agent reads MNPR's filings, financials, insider trades and 13F holders, then answers with sources.

Start free